electroCore,

electroCore, OpEx/Revenue

The Operating Expenses to Revenue Ratio of electroCore, (ECOR) as of Oct 17, 2026 is 127.81 %. In the previous year, Operating Expenses to Revenue Ratio was 133.27 % — a change of -4.09% (lower).

OpEx/Revenue

127.81 %

YoY

-4.09%

Last updated:

Operating Expenses to Revenue Ratio of electroCore, is 2025 127.81 % . Operating Expenses to Revenue Ratio of electroCore, was 2024 133.27 % . It decreases by -4.09% lower compared to the previous year.

The electroCore, OpEx/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OpEx/Revenue
Date
OpEx/Revenue
Jan 1, 2018
5,535.78 USD
Jan 1, 2019
1,896.20 USD
Jan 1, 2020
120.80 USD
Jan 1, 2021
442.29 USD
Jan 1, 2022
347.42 USD
Jan 1, 2023
198.15 USD
Jan 1, 2024
133.27 USD
Jan 1, 2025
127.81 USD
The electroCore, OpEx/Revenue history
YEAROpEx/RevenueYoY
127.81 %-4.09%
133.27 %-32.74%
198.15 %-42.97%
347.42 %-21.45%
442.29 %+266.12%
120.80 %-93.63%
1,896.20 %-65.75%
5,535.78 %+73.19%
3,196.41 %-46.35%
5,957.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

electroCore, Stock analysis

What does electroCore, do? electroCore, Inc. is a medical device company based in Basking Ridge, New Jersey, operating in the Health Care sector. The company focuses on non-invasive vagus nerve stimulation (nVNS) therapy, offering a hand-held device called gammaCore. This device provides non-drug treatment for adults experiencing episodic cluster and migraine pain. electroCore's technology targets primary headaches, including migraine and cluster headache, as well as related chronic conditions such as gastric motility disorders, psychiatric issues, sleep disorders, and pain disorders. The company went public via an IPO on June 22, 2018, and currently employs 83 full-time staff. Its headquarters are located in Basking Ridge, and it operates within the Health Care industry. electroCore's primary product, gammaCore, is designed for non-invasive cervical vagus nerve stimulation, aiming to address neurological, psychiatric, gastroenterological, and respiratory conditions. The company's website is https://www.electrocore.com/. electroCore is listed under the ticker ECOR with ISIN US28531P2020. The firm's commercial stage operations emphasize non-invasive therapeutic solutions without pharmaceutical intervention. electroCore, is one of the most popular companies on Eulerpool.

Frequently Asked Questions about electroCore, stock

Operating Expenses to Revenue Ratio of electroCore, is 127.81 % in 2025.

Operating Expenses to Revenue Ratio of electroCore, changed from 133.27 % to 127.81 %, representing a -4.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Expenses to Revenue Ratio electroCore, since 2006 – with annual values, charts, and detailed analysis.

The OpEx/Revenue ratio measures total operating expenses as a percentage of revenue. Declining ratios suggest improving operational leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Expenses to Revenue Ratio's electroCore, with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Expenses to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Expenses to Revenue Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — electroCore,

All Key Metrics — electroCore,